JPMorgan analyst Anupam Rama lowered the firm’s price target on Sarepta (SRPT) to $84 from $169 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect its lower net product guidance and lower peak sales or Elevidys.
Claim 30% Off TipRanks
Trade SRPT with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Positive Outlook for Sarepta Therapeutics Amid Elevidys Expansion and Strategic Collaborations
- Sarepta reports positive ELEVIDYS protein expression data in young patients
- Sarepta presents EMBARK study data at ASGCT conference
- Sarepta Therapeutics: Hold Rating Amid Limited Financial Gains from ELEVIDYS Approval and Market Adoption Concerns
- Sarepta announces Japan approval for Elevidys